E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors

Modern Pathology

Volumn 15, Issue 10, 2002, Pages 1038-1043

  Volante, Marco ^a   Croce, Sabrina ^a   Pecchioni, Carla ^a   Papotti, Mauro ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cell cycle; E2F 1; Immunohistochemistry; Oxyphilic; Retinoblastoma pathway; Thyroid tumors

Indexed keywords

CELL CYCLE PROTEIN; KI 67 ANTIGEN; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID TUMOR;

ADENOCARCINOMA; ADENOMA, OXYPHILIC; ADULT; CELL COUNT; CELL CYCLE PROTEINS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036790612     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000028645.36632.A8     Document Type: Article

References (40)

1. Nesland JM, Sobrinho Simoes M, Holm R, Sambade MC, Johannessen JV. Hurthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunohistochemistry. Ultrastruct Pathol 1985;8:269-90.
2. Tallini G. Oncocytic tumors. Virchows Arch 1998;433:5-12.
3. Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF. Invasive Hurthle cell carcinoma of the thyroid: natural history and management. Mayo Clinic Proc 1984;59:851-5.
4. Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J. Follicular Hurthle cell tumors of the thyroid gland. Cancer 1991;68:1944-53.
5. Rosai J, Carcangiu ML, De Lellis RA. Tumors of the thyroid gland. In: Atlas of tumor pathology. Washington, D.C.: Armed Forces Institute of Pathology; 1992. p. 161-82.
6. LiVolsi VA. Surgical pathology of the thyroid. Philadelphia: WB Saunders; 1990. p. 275-88.
7. Lazzereschi D, Sambuco L, Carnovale Scalzo C, Ranieri A, Mincione G, Nardi F, et al. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 1998;76:806-11.
8. Wang S, Wuu J, Savas L, Patwardhan N, Khan A. The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol 1998;29:1304-9.
9. Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA, Khan A. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol 2000;13: 882-7.
10. Erickson LA, Jin L, Goellner JR, Lohse C, Pankratz VS, Zukerberg LR, et al. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol 2000;13:186-92.
11. Basolo F, Caligo MA, Pinchera A, Fedeli F, Baldanzi A, Miccoli P, et al. Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. Thyroid 2000;10:741-6.
12. Holm R, Nesland JM. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 1994;172:267-72.
13. Iuliano R, Trapasso F, Stella A, Le Pera I, Melillo RM, Bruni P, et al. Pivotal role of the RB family proteins in in vitro thyroid cell transformation. Exp Cell Res 2000;260:257-67.
14. Anwar F, Emond MJ, Schmidt RA, Hwang HC, Bronner MP. Retinoblastoma expression in thyroid neoplasms. Mod Pathol 2000;13:562-9.
15. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998;11:169-74.
16. Resnick MB, Schacter P, Finkelstein Y, Kellner Y, Cohen O. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod Pathol 1998;11:735-9.
17. Erickson LA, Yousef OM, Jin L, Lohse CM, Pankratz VS, Lloyd RV. p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma. Mod Pathol 2000;13:1014-9.
18. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, et al. Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 1999;23:678-85.
19. Shi Y, Zou M, Farid NR, al-Sedairy ST. Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. Br J Cancer 1996;74: 1336-41.
20. Jones CJ, Shaw JJ, Wyllie FS, Gaillard N, Schlumberger M, Wynford-Thomas D. High frequency deletion of the tumour suppressor gene P16INK4a (MTS1) in human thyroid cancer cell lines. Mol Cell Endocrinol 1996;116:115-9.
21. Elisei R, Shiohara M, Koeffier HP, Fagin JA. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 1998;83: 2185-93.
22. Papotti M, Torchio B, Grassi L, Favero A, Bussolati G. Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid. Am J Surg Pathol 1996;20:686-94.
23. Qin XQ, Livingston DM, Kaelin WG Jr, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A 1994;91:1918-22.
24. Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A 1994;91:3602-6.
25. Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994;371:72-4.
26. Anwar F. The concurrent expression of retinoblastoma protein and E2F-1 family of transcription factors define a unique phenotype of Hurthle and Warthin-like variants of papillary carcinoma different from regular papillary carcinoma. Mod Pathol 2001;14:74A.
27. Lai R, Medeiros LJ, Wilson CS, Sun NC, Koo C, McCourty A, et al. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod Pathol 1998;11: 642-7.
28. Lai R, Medeiros LJ, Coupland R, McCourty A, Brynes RK. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol 1998; 11:457-63.
29. Moller MB, Kania PW, Ino Y, Gerdes AM, Nielsen O, Louis DN, et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia 2000;14:898-904.
30. Yasui W, Naka K, Suzuki T, Fujimoto J, Hayashi K, Matsutani N, et al. Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma. Oncol Rep 1999;6:983-7.
31. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer 1999;81:535-8.
32. Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, et al. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst 1999;91:874-81.
33. Volante M, Papotti M, Gugliotta P, Migheli A, Bussolati G. Extensive DNA fragmentation in oxyphilic cell lesions of the thyroid. J Histochem Cytochem 2001;49:1003-11.
34. Bussolati G, Gugliotta P, Volante M, Pace M, Papotti M. Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology 1997;31:400-7.
35. Adams JC. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stain. J Histochem Cytochem 1992;40:1457-63.
36. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) in bladder cancer. Oncogene 1999;18:1197-203.
37. Yamasaki L. Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action. Biochim Biophys Acta 1999;1423:M9-15.
38. Formigli L, Papucci L, Tani A, Schiavone N, Tempestini A, Orlandini GE, et al. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J Cell Physiol 2000;182:41-9.
39. Maximo V, Soares P, Rocha AS, Sobrinho Simoes M. The common deletion of mitochondrial DNA is found in goiters and thyroid tumors with and without oxyphilic cell change. Ultrastruct Pathol 1998;22:271-3.
40. Muller-Hocker J, Jacob U, Seibel P. Hashimoto thyroiditis is associated with defects of cytochrome-c oxydase in oxyphilic Askanazy cells and with the common deletion (4,977) of mitochondrial DNA. Ultrastruct Pathol 1998;22: 91-100.